Literature DB >> 16040392

Elimination of alloreactive T cells using photodynamic therapy.

R Sidi Boumédine1, D C Roy.   

Abstract

GvHD, the most important cause of morbidity and mortality after allogeneic stem cell transplantation, depends primarily on the ability of a donor T-cell subset to react to immunogenic host Ag. Recently developed culture conditions and treatment strategies may bring us closer to the selective elimination of such alloreactive T cells, often considered the holy grail of transplantation. Among the various therapeutic modalities, photodynamic therapy (PDT) offers a biological and global approach to the eradication of unwanted allo-activated T cells by combining mitochondrial targeting, P-glycoprotein inhibition and reactive oxygen species production. Indeed, the high potency of PDT against malignant cells has been harnessed to exert selective and extensive elimination of alloreactive T-cell subsets mediating GvHD, while preserving resting T cells with the ability to reconstitute the immune system for GvL activity and prevent or suppress viruses and fungi. The present paper reviews the basis of the PDT strategy, and the methodology employed. In vitro and in vivo studies that formed the proof of principle as a basis for human studies to investigate the clinical potential of PDT in the context of GvHD will be presented together with insights into future clinical applications of this versatile treatment platform.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040392     DOI: 10.1080/14653240510027109

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  8 in total

Review 1.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

2.  Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

Authors:  Lori Muffly; Kevin Sheehan; Randall Armstrong; Kent Jensen; Keri Tate; Andrew R Rezvani; David Miklos; Sally Arai; Judith Shizuru; Laura Johnston; Everett Meyer; Wen-Kai Weng; Ginna G Laport; Robert S Negrin; Sam Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2018-03-27

Review 3.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

Review 4.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

Review 5.  Photodynamic therapy induces an immune response against a bacterial pathogen.

Authors:  Ying-Ying Huang; Masamitsu Tanaka; Daniela Vecchio; Maria Garcia-Diaz; Julie Chang; Yuji Morimoto; Michael R Hamblin
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 6.  Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.

Authors:  Monzr M Al Malki; Richard Jones; Qing Ma; Dean Lee; Yair Reisner; Jeffrey S Miller; Peter Lang; Suradej Hongeng; Parameswaran Hari; Samuel Strober; Jianhua Yu; Richard Maziarz; Domenico Mavilio; Denis-Claude Roy; Chiara Bonini; Richard E Champlin; Ephraim J Fuchs; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-12       Impact factor: 5.742

7.  Tracking and treating activated T cells.

Authors:  N H Kim; V Nadithe; M Elsayed; O M Merkel
Journal:  J Drug Deliv Sci Technol       Date:  2013-01-01       Impact factor: 3.981

8.  ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Authors:  Denis Claude Roy; Irwin Walker; Johan Maertens; Philippe Lewalle; Eduardo Olavarria; Dominik Selleslag; Sylvie Lachance; Marc Buyse; Kun Wang; Jeroen Rovers; Irene Santi; Halvard Bonig; Andrew Sandler; Jurjen Velthuis; Stephan Mielke
Journal:  Leukemia       Date:  2020-02-11       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.